Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca To Continue Collaboration With Shionogi On Crestor

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca CEO David Brennan stated Oct. 8 that the company will keep the same relationship with Japanese pharmaceutical company Shionogi, after Shionogi's purchase of American firm Sciele Pharma. Currently, AstraZeneca and Shionogi are collaborating in marketing hyperlipidemia drug Crestor (rosuvustatin). Brennan also disclosed that the company will keep the current staff level of 3,200 in Japan, amid its effort to cut work force and streamline operations in the U.S. and Europe. Shionogi launched the take over bid for Sciele in September and completed the bid Oct. 6 in an effort to strengthen the company's sales network in the U.S. market. (Click here for more - Japanese language) "AstraZeneca To Continue The Same Relationship With Shionogi - AstraZeneca CEO" - Nikkei Sangyo News (10/8/08)

You may also be interested in...

One Hundred Years Later, Eli Lilly And Shionogi Hold Onto Cross-Pacific Partnership

Indianapolis-based Eli Lilly has been able to maintain a partnership with Osaka-headquartered Shionogi for exactly one century. Their relationship started when Shionogi started importing gelatin capsules from Lilly back in 1909. Alliance managers from Lilly and Shionogi sat down with PharmAsia News' Tokyo bureau to talk about what has made the partnership so successful.

‘Open & Constructive’: Early Feedback Supports Simultaneous Scientific Advice In Europe

A European pilot project that lets drug companies developing innovative products receive scientific advice from two EU member states at the same time is proving its worth during the pandemic.

Australia’s TGA Seeks Feedback on Data Matrix Code Labelling

The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts